Analyzing Align Technology (ALGN) through an Investor's Lens

By Harris Dyer • Wednesday, July 29 16:01 • Permanent Link

Large-cap Health Care company Align Technology has moved 2.6% so far today on a volume of 1,288,616, compared to its average of 1,003,560. In contrast, the S&P 500 index moved -2.0%.

Align Technology trades -14.36% away from its average analyst target price of $210.29 per share. The 14 analysts following the stock have set target prices ranging from $175.0 to $240.0, and on average have given Align Technology a rating of buy.

Anyone interested in buying ALGN should be aware of the facts below:

Align Technology's current price is 113.8% above its Graham number of $84.21, which implies that at its current valuation it does not offer a margin of safety
Align Technology has moved -13.7% over the last year, and the S&P 500 logged a change of 16.8%
Based on its trailing earnings per share of 5.95, Align Technology has a trailing 12 month Price to Earnings (P/E) ratio of 30.3 while the S&P 500 average is 29.3
ALGN has a forward P/E ratio of 14.6 based on its forward 12 month price to earnings (EPS) of $12.38 per share
The company has a price to earnings growth (PEG) ratio of 0.89 — a number near or below 1 signifying that Align Technology is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 3.11 compared to its sector average of 3.19
Align Technology, Inc. provides Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services in the United States, Switzerland, and internationally.
Based in Tempe, the company has 20,275 full time employees and a market cap of $12.9 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.